BNP Paribas Knock-Out TDXP/ DE000PB5GMJ1 /
23/08/2024 21:20:18 | Chg.+0.060 | Bid21:56:34 | Ask21:56:34 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
16.840EUR | +0.36% | 16.860 Bid Size: 1,000 |
17.040 Ask Size: 1,000 |
TECDAX | 1,652.1032 EUR | 31/12/2078 | Call |
GlobeNewswire
22/07
MiddleGround Capital enters into Investment Agreement with STEMMER IMAGING AG and announces intentio...
GlobeNewswire
12/06/2018
Software AG acquires Technology Scale-up TrendMiner for analysis and visualization of time series da...
GlobeNewswire
13/12/2016
MorphoSys Starts Phase 2 Trial of MOR208 in Combination with Idelalisib in Patients with Relapsed or...
GlobeNewswire
06/12/2016
MorphoSys Presents Updated Clinical Data for Blood Cancer Candidate MOR208 in NHL and CLL at ASH 201...
GlobeNewswire
06/12/2016
MorphoSys Presents Updated Clinical Results for Anti-CD38 Antibody MOR202 at ASH 2016
GlobeNewswire
28/11/2016
MorphoSys Announces That Its Licensee Janssen Has Submitted a Marketing Authorisation Application Fo...
GlobeNewswire
17/11/2016
MorphoSys Announces That Its Licensee Janssen Has Submitted Biologics License Application For Guselk...
GlobeNewswire
15/11/2016
MorphoSys Announces That Its Licensee Janssen Has Presented Positive Clinical Data of Guselkumab in ...
GlobeNewswire
08/11/2016
Anke Linnartz joins MorphoSys as Head of Corporate Communications and Investor Relations
GlobeNewswire
03/11/2016
MorphoSys Announces Presentations of Clinical Data at Upcoming American Society of Hematology (ASH) ...
GlobeNewswire
02/11/2016
MorphoSys and LEO Pharma Enter into Strategic Alliance to Develop Therapeutic Antibodies in Dermatol...
GlobeNewswire
20/10/2016
MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial with Novel Cancer Antibody
GlobeNewswire
17/10/2016
MorphoSys Presents Updated Clinical Results for MOR202 at Medical Conference